Cortex drops bid to test drug for ADHD
Cortex Pharmaceuticals says that the FDA has turned thumbs down on its INDA for a Phase IIb trial of CX717 for ADHD after reviewing its animal toxicology studies. Cortex says its asking FDA officials to inactivate the INDA for that indication. Studies of CX717 will go ahead for respiratory depression and its Alzheimer's disease PET scan.
- see the release from Cortex
Related Articles:
Cortex gets green light to resume Alzheimer's trials. Report
FDA hold lifted on Cortex drug. Report
Cortex shares plunge on CX717 failure. Report
Cortex names Varney new COO. Report
Read more on: ADHD
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
